APPENDIX A and B

APPENDIX A and B.doc

Examination of Online Direct-to-Consumer Prescription Drug Promotion

APPENDIX A and B

OMB: 0910-0714

Document [doc]
Download: doc | pdf

APPENDIX A

Title 21 Food and Drugs
§ 202.1   Prescription-drug advertisements.

(e) True statement of information in brief summary relating to side effects, contraindications, and effectiveness:

(5) “True statement” of information. An advertisement does not satisfy the requirement that it present a “true statement” of information in brief summary relating to side effects, contraindications, and effectiveness if:

(i) It is false or misleading with respect to side effects, contraindications, or effectiveness; or

(ii) It fails to present a fair balance between information relating to side effects and contraindications and information relating to effectiveness of the drug in that the information relating to effectiveness is presented in greater scope, depth, or detail than is required by section 502(n) of the act and this information is not fairly balanced by a presentation of a summary of true information relating to side effects and contraindications of the drug; Provided, however, That no advertisement shall be considered to be in violation of this section if the presentation of true information relating to side effects and contraindications is comparable in depth and detail with the claims for effectiveness or safety.

(iii) It fails to reveal facts material in the light of its representations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the advertisement.

Appendix B




2


File Typeapplication/msword
File TitleAPPENDIX A
Authorjuanmanuel.vilela
Last Modified ByCTAC
File Modified2012-06-30
File Created2012-06-30

© 2024 OMB.report | Privacy Policy